Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab ...

Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) ...

Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Ever wondered where 'KOLs' came from and why they matter? Dr Alex Loveday answers those questions in this latest edition of ...

Dive into a comprehensive exploration of the latest trends and cutting-edge strategies in medical publication planning. Our ...

Kate Shaw, founder and CEO of Innovative Trials, a global clinical trial patient recruitment and retention company, won the ...

Post-treatment follow-up of patients is not new. Traditional follow-up studies may last two to five years, while long-term ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...

In a significant stride toward fostering diversity and inclusivity in dermatology, Medscape Education and the Comprehensive Medical Mentoring Program (CMMP) have established a unique alliance to ...